March 02, 2026 13:00 ET  | Source: Smith & Nephew UK Ltd Uniting the most advanced technologies for biomechanical repair and biological augmentation  Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it will showcase its unrivalled portfolio for rotator cuff repair (RCR) during the 2026 American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting in New […]

March 2, 2026 VANCOUVER, British Columbia and NEW YORK, March 02, 2026 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME) and Royalty Pharma plc (Nasdaq: RPRX) today announced an agreement for $250 million in funding from Royalty Pharma in the form of a non-recourse royalty-backed note with repayments due from 30% of worldwide tiered royalties on Ziihera® (zanidatamab-hrii) owed to Zymeworks from Jazz Pharmaceuticals (Jazz) and BeOne Medicines (BeOne). “This

March 02, 2026 08:30 ET  | Source: Biomimetic Innovations Ltd SHANNON, Ireland, March 02, 2026 (GLOBE NEWSWIRE) — Biomimetic Innovations Ltd, an affiliate of PBC Biomed, an Irish medical device company specialising in biomimetic materials, today announced approval by MHRA for a first-in-human clinical study evaluating the safety and early performance of OsStic™ in periarticular fractures. The study

March 31, 2026 14:13 ET  | Source: Pineal Capital Management DUBLIN, March 31, 2026 (GLOBE NEWSWIRE) — The following is an open letter issued by Pineal Capital Management: Board of DirectorsTeladoc Health, Inc.2 Manhattanville Road, Suite 203Purchase, NY 10577 31st March 2026 **See disclaimers at end of letter** Dear Members of the Board, Management and Fellow Stakeholders, Pineal

February 26, 2026 13:50 ET  | Source: Boehringer Ingelheim Limited This press release is not intended for UK media Ingelheim, Germany and Ridgefield, Conn. [DATE] — The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim’s HERNEXEOS® (zongertinib tablets) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine

February 26, 2026 10:00 ET  | Source: Curium BOSTON, Feb. 26, 2026 (GLOBE NEWSWIRE) — Curium, a world leading nuclear medicine company dedicated to using cutting-edge technology and innovative science to personalize diagnoses and treatments for patients with cancer, today announced the first dosimetry and pharmacokinetics (PK) data from a substudy of the ongoing pivotal Phase 3

February 26, 2026 07:05 ET  | Source: Boehringer Ingelheim Limited Ingelheim, Germany, Oxford, UK and Boston, USA, 26, February 2026 – Boehringer Ingelheim and Sitryx Therapeutics (“Sitryx”), a clinical-stage biopharmaceutical company developing novel oral therapies to restore immune balance in autoimmune and inflammatory diseases, today announced that Boehringer has acquired an exclusive license for a preclinical, small molecule program from

February 24, 2026 19:30 ET  | Source: Junshi Biosciences SHANGHAI, Feb. 24, 2026 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the company has entered into the strategic collaboration with Antengene Corporation Limited (“Antengene”,

February 24, 2026 16:30 ET  | Source: Teva Pharmaceutical Industries Ltd PARSIPPANY, N.J. and TEL AVIV, Israel, Feb. 24, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva’s President and CEO, will participate in the upcoming investor conferences in March as follows: To access live webcasts of the

Raising funds to advance high-impact mitochondrial research with applications across rare disease, neurodegeneration, and healthspan February 24, 2026 12:57 ET  | Source: Countdown For A Cure A Media Snippet accompanying this announcement is available by clicking on this link. ATLANTA, Feb. 24, 2026 (GLOBE NEWSWIRE) — Countdown For A Cure (CFAC) hosted its third annual Evening of

The GYDER® Navigation System is the world’s first commercially available pin-less & image-less computer assisted technology for real time guidance during Total Hip Arthroplasty using the Anterior Approach February 22, 2026 11:05 ET  | Source: Gyder Surgical PALO ALTO, Calif. and MULGRAVE, Australia, Feb. 22, 2026 (GLOBE NEWSWIRE) — Gyder Surgical, a MedTech company specializing in intuitive, non-invasive orthopedic navigation

February 20, 2026 14:43 ET  | Source: Teva Pharmaceutical Industries Ltd PARSIPPANY, N.J. and TEL AVIV, Israel and PARIS, Feb. 20, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Medincell (Euronext: MEDCL), announced today that the U.S. Food and Drug Administration (FDA) has accepted its New

February 19, 2026 04:00 ET  | Source: Royal Philips February 19, 2026 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today published its Annual Report 2025. Philips’ Annual Report 2025 will be on the agenda of the Annual General Meeting of Shareholders (AGM), to be held on May 8, 2026. The

Adds to executive focus on early clinical development and deepens medical and scientific partnership with clients February 17, 2026 07:00 ET  | Source: Fortrea Holdings Inc DURHAM, N.C., Feb. 17, 2026 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced it has expanded its executive team. Oren

February 17, 2026 06:00 ET  | Source: Teva Pharmaceutical Industries Ltd Teva will hold an investor call and live webcast today,Tuesday, February 17, 2026, at 8:00 a.m. ET to discuss these data. PARSIPPANY, N.J. and PARIS, Feb. 17, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: